---
title: "Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295576589.md"
description: "Encouraging results from Phase 2 CRDF-004 study were shared in a presentation at ASCO. The data backs the progression of a combination of 30 mg onvansertib with FOLFIRI/bevacizumab for the treatment of first-line RAS-mutated metastatic colorectal cancer (mCRC). The positive outcomes support moving forward with the planned registrational program for this treatment regimen."
datetime: "2026-08-11T20:13:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295576589.md)
  - [en](https://longbridge.com/en/news/295576589.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295576589.md)
generator: "portal-rs"
---

# Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Encouraging results from Phase 2 CRDF-004 study were shared in a presentation at ASCO. The data backs the progression of a combination of 30 mg onvansertib with FOLFIRI/bevacizumab for the treatment of first-line RAS-mutated metastatic colorectal cancer (mCRC). The positive outcomes support moving forward with the planned registrational program for this treatment regimen.

### Related Stocks

- [CRDF.US](https://longbridge.com/en/quote/CRDF.US.md)

## Related News & Research

- [William Blair downgrades Cardiff Oncology (CRDF) to a Hold](https://longbridge.com/en/news/295587034.md)
- [Cardiff Oncology Q2 operating expenses fall on lower R&D costs](https://longbridge.com/en/news/295577294.md)
- [Nuveen Multi-Asset Income Fund declares $0.116 dividend](https://longbridge.com/en/news/297950236.md)
- [Chosa Oncology enters non-exclusive licensing pact with Aida Oncology](https://longbridge.com/en/news/297188055.md)
- [Nuveen Real Asset Income and Growth Fund declares $0.1335 dividend](https://longbridge.com/en/news/297949729.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**